IMM News: Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting - 28th Apr 2022, 10:00pm

annb0t

Top 20
Immutep Limited

SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from first line non-small cell lung cancer patients (Part A) of the Phase II TACTI-002 trial has been selected for a prestigious Oral Presentation at the American Society of Clinical Oncology’s (A...

>>> Read more: Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
 
Top Bottom